FDA OTC drug oversight funded by fees manufacturers will pass to consumers
H.R. 4273 — Over-the-Counter Monograph Drug User Fee Amendments · Filed by Robert Latta (R-OH) · 3 cosponsors · Introduced Jul 2, 2025 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill extends and revises the FDA's user-fee program for over-the-counter (OTC) monograph drugs—non-prescription medications like antacids and cough drops that are sold without individual drug applications. The bill authorizes the FDA to collect facility fees from OTC drug manufacturers from fiscal years 2026–2030, with specific revenue targets and adjustment mechanisms. The fees fund FDA review and oversight of OTC monograph drugs, and the bill includes technical updates to the fee structure, inflation adjustments, and a one-time workload adjustment option for fiscal years 2028–2030.
Why we flagged it
The bill's core function is straightforward—reauthorizing FDA user fees for OTC drug oversight through 2030. However, the inclusion of 'voluntary consensus standards' language and specific dollar-amount carve-outs (e.g., $2.373M for FY2026) suggests accommodation of industry preferences within the fee structure, blending public oversight with private-sector input.
What the text implies
- The 'voluntary consensus standard' definition in Section 3 may allow OTC drug manufacturers to influence testing procedures through industry-led standards bodies, potentially weakening FDA oversight if those standards are less stringent than FDA-mandated testing.
- The one-time facility fee workload adjustment (Section 4, paragraph 4) is triggered only if average OTC facilities exceed 1,625 AND fewer than 30% are on arrears lists—a narrow condition that may never activate, leaving the adjustment as a contingent benefit to manufacturers if market conditions align.
The full analysis lists 5 implications of this text.
Who stands to gain
OTC drug manufacturers and facility operators (fee-funded FDA oversight reduces their compliance unc; Standards development organizations (increased industry reliance on voluntary consensus standards); FDA (fee revenue dedicated to OTC monograph activities)